Worse Outcomes With Irinotecan and Temolozomide in Ewing Sarcoma
Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.
Sarcoma News
SARCOMA CANCER ADVISOR
Sarcoma News
Standard Chemotherapy Regimen in US Improved Outcomes in Ewing Sarcoma
A chemotherapy regimen that is standard in the US for patients with Ewing sarcoma appeared to improve outcomes, a randomized phase 3 trial showed.
Immune-Related Adverse Events Linked to Better Outcomes in Sarcoma
Patients with advanced sarcoma who developed immune-related adverse events after immune checkpoint blockade were more likely to have a clinical benefit.
Binimetinib Combo Shows Clinical Activity in Advanced GIST
Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.
Trial Under Way for Novel T-Cell Product in Advanced Synovial Sarcoma
A phase 2 trial is under way to evaluate an investigational autologous T-cell product in patients with advanced synovial sarcoma as well as other tumor types.
Trial Under Way for PARP Inhibitor Combo in Uterine Leiomyosarcoma
A single-arm phase II clinical trial is underway to evaluate temozolomide and olaparib as a treatment combination for patients with advanced uterine leiomyosarcoma.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Histology-Tailored Neoadjuvant Chemotherapy Produces Limited Results in Multinational Study on High-Risk Soft Tissue Sarcoma
Histology-tailored neoadjuvant chemotherapy failed to show superiority compared with standard neoadjuvant chemotherapy in patients with high-risk STS.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Pomalyst Gets Accelerated Approval for Kaposi Sarcoma
This indication was granted accelerated approval based on overall response rate (ORR) and continued approval may be contingent upon confirmatory trial results.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Angiosarcoma Research Project Produces Windfall of Druggable Insights
A novel patient-centered approach aids the collection of research on a rare cancer.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
